A group of bioengineers have developed a noninvasive, portable device that resembles a finger-worn, pulse oximeter to count white blood cells. They have three workable prototypes that are being tested with chemotherapy patients to track their immune system in real-time. The researchers aim to have an initial beta product that it can support via crowdfunding in 2017, with a product on the market potentially in 2019.
Royal Philips and the Massachusetts Institute of Technology have teamed up to develop a noninvasive means of measuring intracranial pressure to detect brain injuries. It's expected to incorporate Philips' ultrasound technology and MIT's physiological modeling.
Hedge fund managers are so flush that now they're giving money away. A pair of prominent fund heads have led a collection of wealthy individuals to back a project at the Broad Institute of MIT and Harvard researching the bacteria behind tuberculosis with $20 million. The goal is to better understand the bacteria itself, as well as how drug resistance forms in it and to develop a rapid diagnostic test for drug-resistant TB.
MIT's Hacking Medicine program, which studies digital health and medicine, is set to become a nonprofit institute devoted to empirically evaluating the real-world effectiveness of the latest medical gadgets, gizmos, smartphone apps and the like.
Researchers from MIT demonstrated that a 3-mm-long microdevice holding up to 16 different drugs and drug combinations can release those drugs when implanted directly in a tumor to then determine the tumor's sensitivity to those therapies.
Royal Philips and the Massachusetts Institute of Technology (MIT) have partnered in a 5-year research alliance with a $25 million budget to develop novel product solutions in healthcare and lighting.
An MIT team is developing implants that can withstand attacks from the body's immune system, which generally treats foreign objects as invaders.
Myomo has raised an initial $5 million tranche of a Series B round to help it to market its MyoPro Myoelectric Arm Orthosis. The round was from existing investors and led by Mountain Group.
Germany's Bayer already partners with MIT and Harvard on oncology research, and now the partnership is being upgraded to include cardiovascular genomics and drug discovery. The expansion of the alliance into cardiovascular genomics will be about the search for genetic biomarkers of patient risk or suitability to particular drugs that treat cardiovascular conditions like heart disease.
A team of MIT scientists has designed a new injectable hydrogel made from nanoparticles that could someday be used to hold drugs in the body, treating diseases such as cancer, macular degeneration and heart disease.